#ZydusLife ’s US arm Sentynl Therapeutics acquires worldwide proprietary rights to Zokinvy at net base price of $45 million from US-based Eiger Biopharmaceuticals

Alert | Zokinvy is approved for the treatment of a collection of ultra-rare, fatal, genetic premature aging diseases

⚡️ #ZYDUSLIFE Subsidiary Sentynl Therapeutics Acquires Global Rights to Zokinvy® from Eiger Biopharmaceuticals for $45.2M. 🤝Zokinvy®, Used to Treat Progeria, Enhances #ZYDUSLIFE 's Rare Disease Portfolio, Boosting its Global Presence. 🚀

Sentynl Therapeutics acquires Eiger BioPharmaceuticals's Zokinvy program to expand portfolio in rare diseases business-news-today.com/sentynl-therap… #Zokinvy #RareDiseaseTreatment #SentynlTherapeutics

Zydus Lifesciences:

Sentynl Therapeutics Announces Global Acquisition Of Zokinvy (Lonafarnib) For Treatment Of Hutchinson-Gilford Progeria Syndrome From Eiger Biopharmaceuticals

During #BrainTumorAwarenessMonth , we’re committed to shining a light on the profound impact the disease has on children and their families, and the crucial need for more research, treatment options, and support. Join us in raising awareness as we #GoGrayInMay

Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has acquired the worldwide proprietary rights to Zokinvy treatment from Eiger Biopharmaceuticals for ~$45 million

Zokinvy is the 1st & only USFDA approved treatment to target the cause & symptoms of Progeria

This report on the Indian ITES sector by ITIF points to the current primary manufacturing edge in India, which exists in biopharmaceuticals. It is evident that India can competitively manufacture biosimilars, APIs, and vaccines at scale, 11/n
itif.org/publications/2…

Zydus Life: Sentynl Therapeutics (US-based biopharma company wholly-owned by Zydus Lifesciences) announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from #Eiger Biopharmaceuticals

As many of you know, I do like to write things - Sam Blackman
Day One Biopharmaceuticals

#Cancer #Biopharmaceuticals #OncoDaily #Oncology #PatientCare

oncodaily.com/59454.html

I found you a Three Black Crows Candle Pattern on the daily chart of XTL Biopharmaceuticals Ltd.

$h2k2 #h2k2 #bearish #f #xfra

penketrading.com/symbols/H2K2.F/

A new oral therapeutic for children diagnosed with pediatric low-grade glioma (pLGG) has received approval by the Food and Drug Administration!

Click below to view the press release from the manufacturer, Day One Biopharmaceuticals.

bit.ly/3UoSRdN

Join Dr. Ajay Singh, Head - mRNA at Gennova Biopharmaceuticals, for an insightful case study on 'mRNA Vaccine from Concept to Clinic' at #ETBIOMOLECULE .

Know More: bit.ly/3VnjQIN

#ETPHARMA #PEPTIDES #OLIGONUCLEOTIDE #BiomoleculeInnovations #AdvancedTherapeutics #MRNA

$PVCT Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia) globenewswire.com/en/news-releas… #RoseBengal Sodium #RoseBengal #hematology #leukemia UCalgary Medicine U Calgary

Join Professor Ashutosh Kumar, Structural Biology, Department of Bioscience and Bioengineering, IIT Bombay as he takes us on a journey inside 'Zooming inside HOS of in-formulation state Biopharmaceuticals by NMR spectroscopy' at #ETBIOMOLECULE .

Know More: bit.ly/3VnjQIN

We optimized a dispensing application for bioreactor feeding using automation that increased reliability and accuracy. Read about it: prker.co/3tbGA2P #Biopharmaceuticals #LifeSciences

$XFOR This is a great question! You should know the answer to this one! But I will answer. The drug is called Ojemda by Day One Biopharmaceuticals $DAWN 33000 per 28 day supply. That’s 33000x 13 = 430k per year.

Considering a career in biopharmaceuticals? Check out our Career Day poster series throughout the month of May, which features PhAMA member companies and potential opportunities!

'Leachables and extractables: Safeguarding pharmaceutical purity'

Last call for Leachables and Extractables MasterClass by Dr. Ralph Nussbaum: bit.ly/3WrM9GM

#glceurope #masterclass #leachable #extractables #analyticaltesting #pharmaceuticalindustry #biopharmaceuticals

@Paras Biopharmaceuticals Finland is ready for Biotechgate Digital Partnering from May 13-17th, welcoming discussions on our novel #biologics /biosimilar pipeline, in addition to our complete biologics scale up production services (inc. large scale). Meet us!

#biosimilars #cdmo